secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2023-10-25T23:59:59+00:00
Accession:  0000950170-23-055209
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Q3 net loss $22.5M; cash $376M; obesity trial fully enrolled
-------------------------------------------------------------------

- Net loss of $22.5M ($0.23/sh) vs $15.8M in Q3 2022; R&D expenses $18.4M, up from $12.0M.
- Cash & equivalents $376M at Sept 30, 2023, vs $155.5M at Dec 31, 2022 (includes $287.5M public offering).
- Phase 2 VENTURE trial of VK2735 (GLP-1/GIP agonist) for obesity fully enrolled (n=176); results expected 1H24.
- Phase 1 oral VK2735 study ongoing; data expected 1Q24. Phase 2b VOYAGE (VK2809 for NASH) histology results expected 1H24.
- Phase 1b VK0214 for X-ALD enrolling; enrollment completion expected 4Q23.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017023055209/0000950170-23-055209-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017023055209/vktx-20231025.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-055209

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer